ovarian serous cystadenocarcinoma (Cancer)
Information
- Disease name
- ovarian serous cystadenocarcinoma
- Disease ID
- DOID:5746
- Description
- "An ovary serous adenocarcinoma that has_material_basis_in glandular epithelium, in which cystic accumulations of retained secretions are formed." [url:http\://cancergenome.nih.gov/cancersselected/ovarian, url:http\://en.wikipedia.org/wiki/Serous_cystadenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02142803 | Active, not recruiting | Phase 1 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | May 20, 2014 | October 1, 2024 |
| NCT02111941 | Active, not recruiting | Early Phase 1 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | April 14, 2014 | June 30, 2025 |
| NCT02101775 | Active, not recruiting | Phase 2 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | July 21, 2014 | February 20, 2025 |
| NCT00079430 | Completed | Phase 1 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | June 2004 | |
| NCT00085358 | Completed | Phase 1 | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | May 2004 | |
| NCT00357448 | Completed | Phase 1 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | April 2005 | |
| NCT00466960 | Completed | Phase 2 | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | May 2006 | |
| NCT00814086 | Completed | Phase 1 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | February 2009 | |
| NCT00897442 | Completed | Collecting Tumor Samples From Patients With Gynecological Tumors | June 1992 | ||
| NCT00939809 | Completed | Phase 2 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 2009 | |
| NCT00993616 | Completed | Phase 2 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | December 2009 | July 29, 2012 |
| NCT01074411 | Completed | Phase 1 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | April 5, 2010 | January 27, 2018 |
| NCT01080521 | Completed | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | April 2010 | January 27, 2018 | |
| NCT01294293 | Completed | Phase 1 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | March 2011 | |
| NCT01459380 | Completed | Phase 1 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | October 11, 2011 | February 11, 2017 |
| NCT01489371 | Completed | Phase 1 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 9, 2012 | January 27, 2018 |
| NCT05074472 | Completed | Phase 1/Phase 2 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | January 14, 2022 | September 30, 2023 |
| NCT00059787 | Completed | Phase 2 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | April 2003 | May 2010 |
| NCT00060359 | Completed | Phase 1 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | April 2003 | |
| NCT02283658 | Completed | Phase 2 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | November 14, 2014 | June 21, 2018 |
| NCT00002913 | Completed | Phase 1 | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | December 1996 | |
| NCT02122185 | Suspended | Phase 2 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | February 25, 2015 | February 25, 2025 |
| NCT01275664 | Terminated | N/A | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer | June 2011 | |
| NCT00004221 | Terminated | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | November 1999 | |
| NCT00053235 | Withdrawn | Research Study in Patients With Advanced Ovarian Epithelial Cancer | November 2002 | ||
| NCT01492920 | Withdrawn | Phase 3 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | April 2012 | |
| NCT02050009 | Withdrawn | Phase 1 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 31, 2014 |
- Disase is a (Disease Ontology)
- DOID:3605
- Cross Reference ID (Disease Ontology)
- NCI:C7978
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279663
- Exact Synonym (Disease Ontology)
- serous cystadenoma